tigara Antibody

What is TIGIT and why is it an important target for antibody development?

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a coinhibitory receptor expressed primarily on effector T cells, memory T cells, regulatory T cells (Tregs), and natural killer (NK) cells. It functions as an immune checkpoint molecule that binds to two primary ligands: CD112 (PVRL2, nectin-2) and CD155 (poliovirus receptor, PVR), which are expressed on antigen-presenting cells, fibroblasts, endothelial cells, and some cancer cells .

TIGIT signaling has been shown to inhibit non-Treg and NK cell activation while enhancing the suppressive function of Treg cells. This dual mechanism makes TIGIT antibodies potentially valuable for both cancer immunotherapy (antagonistic antibodies) and autoimmune disease treatment (agonistic antibodies) .

How do agonistic and antagonistic TIGIT antibodies differ in research applications?

TIGIT antibodies can be developed as either agonistic (signal-enhancing) or antagonistic (signal-blocking):

• Agonistic TIGIT antibodies: These enhance TIGIT signaling, which increases the inhibitory effect on T cell activation and potentially enhances Treg suppressive function. Research shows that anti-human-TIGIT agonistic monoclonal antibodies (mAbs) can suppress the activation of CD4+ T cells, particularly follicular helper T (Tfh) and peripheral helper T (Tph) cells that highly express TIGIT. They can also enhance the suppressive function of naive regulatory T cells. These properties make agonistic TIGIT antibodies promising candidates for treating autoimmune conditions .

• Antagonistic TIGIT antibodies: These block TIGIT signaling, potentially enhancing anti-tumor immune responses by releasing the inhibitory effect on effector T cells and NK cells. These are primarily being explored in cancer immunotherapy research.

The selection between these types depends on the specific research objective and disease model being studied .

What is the expression profile of TIGIT in normal and disease states?

TIGIT expression varies across immune cell populations and disease states:

• Normal state: TIGIT is primarily expressed on effector T cells, memory T cells, Tregs, and NK cells. Within the CD4+ T cell compartment, memory subsets show higher expression, with particularly high levels in Tfh (CD45RA-CXCR5+) and Tph cells (CXCR5-PD-1 high) .

• Autoimmune conditions: Studies in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjögren's syndrome (SjS) show altered TIGIT expression patterns. In these conditions, the proportions of Tfh and Tph cells (which highly express TIGIT) are significantly higher in the CD4+ T cell population compared to healthy controls. Similarly, the proportion of CD45RA+ effector memory T (Temra) cells, which also express TIGIT, is significantly higher in the CD8+ T cell population .

This differential expression pattern makes TIGIT a valuable biomarker and potential therapeutic target in both autoimmune and cancer research contexts.

What are the optimal methods for evaluating TIGIT antibody specificity and cross-reactivity?

Assessing TIGIT antibody specificity requires a multi-faceted approach:

• Species cross-reactivity testing: Evaluate binding to TIGIT from different species (human, macaque, mouse) using binding assays. For instance, research has shown that certain anti-human TIGIT antibodies (e.g., M1-8) recognize human and macaque TIGIT but not mouse TIGIT .

• Functional reporter assays: Use luciferase reporter cells to assess agonistic activity, antagonistic activity, and potential cytotoxicity. This allows differentiation between antibodies that have pure agonistic properties versus those with mixed functions .

• T cell suppression assays: Sort TIGIT-expressing cells (such as Tfh cells), label them with proliferation trackers (e.g., CellTrace violet), and culture them with the antibody of interest. Measure cell proliferation by flow cytometry to determine the inhibitory activity of the antibody .

• Mass spectrometry approaches: For TCR-like antibodies, mass spectrometry can be used to identify potential cross-reactive epitopes in human tissues, allowing for comprehensive safety profiling before clinical application .

These methods collectively provide a robust evaluation of antibody specificity and help predict potential off-target effects.

How can researchers effectively measure the functional activity of TIGIT antibodies in vitro?

Several complementary approaches are recommended for assessing TIGIT antibody functionality in vitro:

• Luciferase reporter systems: These systems can measure signaling activity induced by antibody binding. Comparing luminescence values helps determine agonistic versus antagonistic properties .

• T cell subset suppression assays: For agonistic antibodies, measure inhibition of proliferation in sorted T cell subsets (particularly Tfh cells) using flow cytometry after labeling with proliferation dyes like CellTrace violet. Culture the cells with plate-bound anti-CD3 (2 μg/ml), anti-CD28 (1 μg/ml), and the TIGIT antibody (typically 10 μg/ml) for 4-5 days .

• Treg functional enhancement assessment: Measure the antibody's ability to enhance Treg suppressive function by co-culturing Tregs with effector T cells in the presence of the antibody and assessing effector cell proliferation inhibition .

• Cytokine production analysis: Measure changes in cytokine production profiles (particularly immunosuppressive cytokines for agonistic antibodies) using ELISA or cytometric bead arrays.

What animal models are most appropriate for testing TIGIT antibody efficacy in autoimmune conditions?

Based on the research data, several animal models have proven valuable for evaluating TIGIT antibody efficacy in autoimmune conditions:

• Human-TIGIT knock-in mice: These genetically modified mice express human TIGIT instead of mouse TIGIT, allowing direct testing of human-specific TIGIT antibodies. This approach overcomes cross-species reactivity limitations .

• Experimental Autoimmune Encephalomyelitis (EAE): This model for multiple sclerosis has been successfully used to demonstrate the efficacy of anti-human-TIGIT agonistic antibodies. In studies with human-TIGIT knock-in mice, treatment with 100 μg per mouse of anti-human-TIGIT agonistic mAb (administered on days 0, 2, 4, 10, and 17 after immunization with myelin oligodendrocyte peptide) significantly improved clinical scores .

• Imiquimod-induced lupus model: This model effectively mimics systemic lupus erythematosus. When human-TIGIT knock-in mice were treated with topical imiquimod and anti-human-TIGIT agonistic antibody, researchers observed significant suppression of Tfh cells, Tph cells, germinal center B cells, plasma cells, and anti-dsDNA antibody production .

• Collagen-induced arthritis (CIA): Previous studies with TIGIT-deficient mice showed exacerbated symptoms in this model, suggesting that agonistic TIGIT antibodies might be beneficial, though direct testing data with human-TIGIT antibodies in CIA models was not provided in the search results .

When designing these experiments, it's crucial to include appropriate dosing regimens, control groups (isotype antibody), and comprehensive immunophenotyping to fully evaluate therapeutic effects.

How do TIGIT antibodies influence follicular helper T cells and germinal center reactions in autoimmunity?

TIGIT antibodies exhibit significant regulatory effects on follicular helper T (Tfh) cells and subsequent germinal center (GC) reactions, particularly in autoimmune contexts:

• Tfh cell suppression: Anti-human-TIGIT agonistic antibodies have been shown to significantly suppress the proportions of Tfh cells (defined as CXCR5+PD-1+) in CD4+ T cells. This is particularly relevant because Tfh cells express high levels of TIGIT compared to other T cell populations, making them sensitive targets for TIGIT-mediated suppression .

• Downstream GC B cell reduction: As a consequence of Tfh cell suppression, anti-TIGIT agonistic antibodies significantly decrease the proportions of germinal center B cells (defined as CD95+GL7+) and plasma cells (defined as CD19-CD138+). This occurs despite B cells themselves having low TIGIT expression, indicating an indirect mechanism via T cell help modulation .

• Autoantibody reduction: In imiquimod-induced lupus models using human-TIGIT knock-in mice, anti-TIGIT agonistic antibody treatment suppressed the elevation of anti-dsDNA antibodies, a hallmark autoantibody in lupus. This effect was observed alongside the suppression of Tfh cells, GC B cells, and plasma cells, establishing a clear mechanistic pathway .

This cascade of effects (Tfh suppression → GC B cell reduction → plasma cell reduction → autoantibody decrease) demonstrates the potential of TIGIT-targeting strategies to interrupt the autoimmune cycle at multiple points.

What mechanisms underlie the differential effects of TIGIT antibodies on various T cell subsets?

The differential effects of TIGIT antibodies across T cell subsets can be attributed to several key mechanisms:

• Variable TIGIT expression levels: TIGIT is differentially expressed across T cell subsets, with highest expression in memory subsets, especially Tfh and Tph cells within the CD4+ compartment. This variable expression creates naturally different sensitivity thresholds to TIGIT-targeting antibodies .

• Subset-specific signaling pathway integration: TIGIT signaling intersects differently with the dominant signaling pathways in various T cell subsets. In Tfh cells, TIGIT signaling may directly counteract the ICOS and CD28 co-stimulatory signals that drive Tfh differentiation and function .

• Context-dependent receptor-ligand interaction: The availability of TIGIT ligands (CD112 and CD155) varies between different tissue microenvironments and disease states, creating different baseline conditions for TIGIT engagement across T cell populations in different anatomical locations .

• Reciprocal regulation with other immune checkpoints: TIGIT functions within a network of immune checkpoint molecules, including PD-1, CTLA-4, and others. The expression patterns and functional interactions between these checkpoints differ across T cell subsets, creating unique regulatory environments that influence TIGIT antibody effects .

Understanding these mechanisms helps explain why anti-TIGIT agonistic antibodies show particularly strong suppressive effects on Tfh and Tph cells compared to other T cell populations, making them promising candidates for treating diseases with pathogenic Tfh involvement.

How can researchers optimize the development of TCR-like antibodies to minimize cross-reactivity risks?

Developing highly specific TCR-like antibodies requires sophisticated approaches to minimize cross-reactivity risks:

• Mass spectrometry-guided epitope identification: Advanced mass spectrometry techniques can identify the complete interactome of TCR-like antibodies in human tissues. This approach provides direct identification of potential cross-reactive peptides that may not be detected by conventional methods. For example, researchers have used this technique to identify off-target peptide sequences for ESK1, a TCR-like antibody with known off-target activity, in human liver tissue .

• Structural analysis of binding interfaces: Understanding the structural basis of cross-reactivity is crucial. Research has shown that off-target sequences often feature amino acid motifs that allow structural groove-coordination mimicking the target peptide. Identifying these potential "mimic motifs" early in development can help screen out problematic antibody candidates .

• Physiologically relevant testing systems: Use of human primary cells and organ models provides opportunities to evaluate if TCR-like antibodies trigger unintended T cell effector functions. Testing in physiologically relevant models rather than just cell lines can reveal safety issues before clinical application .

• Combination of in silico and experimental approaches: While in silico strategies and predictive modeling are valuable, they should be complemented with experimental validation using the mass spectrometry approach. The predictive specificity of bioinformatic approaches alone is often limited, requiring experimental confirmation of potential off-target interactions .

• Validation in human tissue contexts: Assess off-target binding in situ rather than just in vitro to account for the full complexity of the human tissue environment where these antibodies will ultimately function .

This comprehensive approach significantly increases confidence in the selectivity profile of TCR-like therapeutic candidates before first-in-human clinical applications.

What flow cytometry panels are optimal for evaluating TIGIT expression across immune cell subsets?

For comprehensive evaluation of TIGIT expression across immune cell populations, the following optimized flow cytometry panels are recommended:

Panel 1: Basic T Cell Subset TIGIT Expression

Panel 2: Advanced T Helper Subset TIGIT Analysis

Panel 3: B Cell and Plasma Cell Analysis

When analyzing the data, researchers should:

• Use fluorescence minus one (FMO) controls for accurate TIGIT gating

• Include isotype controls to assess nonspecific binding

• Consider the median fluorescence intensity (MFI) of TIGIT along with percent positive cells, as expression level differences between subsets can be informative

How should researchers interpret contradictory data when testing TIGIT antibody efficacy across different disease models?

When faced with contradictory results across different disease models, researchers should consider several factors:

What quantitative methods best evaluate the therapeutic potential of anti-TIGIT antibodies in preclinical models?

Comprehensive quantitative assessment of anti-TIGIT antibodies requires multiple complementary approaches:

• Clinical scoring systems:

  • For EAE models: Use standardized 0-5 scoring scales assessing tail and limb paralysis

  • For arthritis models: Measure joint swelling and clinical arthritis scores

  • For lupus models: Assess proteinuria, skin lesions, and survival rates

• Immunophenotyping metrics:

  • Proportion changes in key cell populations (Tfh, Tph, Treg, GC B cells, plasma cells)

  • TIGIT expression levels across cell subsets (percentage and MFI)

  • Activation marker dynamics (CD25, CD69, HLA-DR)

• Humoral response measurements:

  • Autoantibody titers (e.g., anti-dsDNA in lupus models)

  • Total immunoglobulin levels by isotype

  • Antigen-specific antibody responses

• Histopathological assessments:

  • Quantitative scoring of tissue inflammation

  • Immunohistochemistry for immune cell infiltration

  • Digital pathology analysis of tissue architecture disruption

• Molecular and transcriptomic analyses:

  • Gene expression changes in target tissues and immune cells

  • Cytokine/chemokine profiles in serum and affected tissues

  • Signaling pathway activation markers

• Statistical approaches for data integration:

  • Principal component analysis to identify key variables

  • Correlation analyses between antibody exposure, immune parameters, and clinical outcomes

  • Multiple regression models to identify predictive biomarkers of response

This multi-parameter approach provides robust quantitative assessment of therapeutic potential while revealing mechanistic insights into antibody function.

How might combination therapies involving TIGIT antibodies be optimized for autoimmune disease treatment?

Optimizing combination therapies with TIGIT antibodies requires strategic consideration of several factors:

• Complementary mechanism selection: Pair TIGIT agonistic antibodies with agents targeting non-overlapping pathways. Since TIGIT primarily impacts T cell function and subsequent B cell responses, combining with agents that directly target:

  • B cell survival (e.g., BAFF/APRIL inhibitors)

  • Innate immune activation (e.g., TLR inhibitors)

  • Tissue-resident inflammatory cells
    may provide synergistic effects .

• Sequential vs. simultaneous administration: Determine whether sequential administration (e.g., TIGIT antibody followed by conventional therapy) or simultaneous treatment optimizes outcomes. This requires systematic comparison in preclinical models measuring:

  • Clinical efficacy parameters

  • Immune cell composition changes

  • Safety profile (with particular attention to infection risk)

• Biomarker-guided combination therapy: Develop predictive biomarkers of response to guide patient selection. Potential biomarkers include:

  • Baseline TIGIT expression on specific T cell subsets

  • Tfh/Treg ratio in peripheral blood

  • Genetic polymorphisms affecting TIGIT pathway components

  • Cytokine profiles reflecting disease subtype

• Dosing optimization: Determine optimal dosing ratios between combination components through systematic dose-ranging studies that assess:

  • Minimum effective dose of each component

  • Potential for dose reduction of conventional therapies

  • Pharmacokinetic/pharmacodynamic interactions

• Long-term maintenance strategies: Investigate whether TIGIT antibodies are most effective as:

  • Induction therapy followed by conventional maintenance

  • Continuous therapy at consistent dosing

  • Intermittent therapy during disease flares

This structured approach to combination therapy development maximizes therapeutic potential while minimizing adverse effects through precise, mechanistically informed treatment strategies.

What novel modifications to TIGIT antibodies might enhance their therapeutic index in autoimmune conditions?

Several innovative antibody engineering approaches could enhance TIGIT antibody efficacy and safety:

• Bispecific antibody formats: Develop bispecific antibodies targeting TIGIT plus a second immune checkpoint (e.g., PD-1, LAG-3) to achieve more comprehensive immune modulation. Alternatively, create bispecifics targeting TIGIT plus a cell type-specific marker to focus activity on particular pathogenic cell populations .

• Fc engineering for enhanced agonism: Modify the Fc region to optimize clustering and signaling through TIGIT. Research on other TNFR family members suggests that:

  • Specific Fc modifications can enhance agonistic activity

  • Altering FcγR binding can modulate antibody function in vivo

  • Engineering antibodies with controlled half-life can improve safety profiles

• Tissue-targeted delivery systems: Develop antibody-drug conjugates or nanoparticle formulations that preferentially accumulate in affected tissues (e.g., joints in arthritis, kidneys in lupus) to reduce systemic immunosuppression.

• Conditional activation mechanisms: Engineer antibodies that become fully active only under specific disease-associated conditions (e.g., in inflammatory microenvironments) using:

  • pH-sensitive binding domains

  • Protease-activatable antibodies

  • Split antibody complementation systems

• Combination with cell-specific targeting: Similar to the TCR-like antibody approach mentioned in the search results, develop antibodies that recognize TIGIT in the context of disease-specific antigen presentation to enhance specificity .

These innovative approaches represent the frontier of therapeutic antibody development and could significantly improve the benefit-risk profile of TIGIT-targeted therapies.

How might advances in immunopeptidomics improve the development of highly specific TCR-like antibodies?

Recent advances in immunopeptidomics offer promising approaches to enhance TCR-like antibody development:

• Mass spectrometry-guided epitope validation: As demonstrated in recent research, mass spectrometry techniques can directly identify the interactome of TCR-like antibodies in human tissues. This approach confirms on-target binding and identifies potential cross-reactive epitopes with unprecedented accuracy .

• De novo identification of cross-reactive peptides: The experimental platform described in the search results enables researchers to identify off-target peptide sequences directly in human tissues, rather than relying solely on predictive modeling. For example, this approach successfully identified cross-reactive peptide sequences for ESK1, a TCR-like antibody with known off-target activity, in human liver tissue .

• Structural motif identification: Advanced immunopeptidomics coupled with structural analysis can identify amino acid motifs that enable cross-reactivity. Research shows that off-target sequences often feature motifs that allow structural coordination mimicking the target peptide. Understanding these patterns early in development can guide antibody optimization .

• Physiologically relevant screening systems: Moving beyond cell lines and library screening, immunopeptidomics in actual human tissues provides a more physiologically relevant context for assessing antibody specificity. This approach addresses limitations of previous methods that failed to detect important off-target interactions .

• Integration with functional validation: Combining immunopeptidomic data with functional assays (e.g., T cell activation, target cell killing) creates a comprehensive pipeline for TCR-like antibody assessment. This integrated approach confirmed that identified off-target epitopes can trigger T cell activation and liver spheroid killing in the case of ESK1 .

These advances collectively represent a significant leap forward in ensuring the safety and specificity of TCR-like antibodies before first-in-human clinical applications, addressing a critical need in this promising therapeutic approach.